Sino Biopharmaceutical (HK:1177) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sino Biopharmaceutical Limited announced promising Phase III clinical trial results for Anlotinib Hydrochloride Capsules in treating advanced renal cell carcinoma, with significantly improved median progression-free survival and objective remission rates compared to the control drug. The new treatment, which is undergoing regulatory review, could potentially become a new standard for first-line therapy, addressing the high incidence and mortality rates of the disease in China.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.